The Technical Analyst
Bausch Health Companies [BHC]
Exchange: NYSE Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
Bausch Health Companies Price, Forecast, Insider, Ratings, Fundamentals & Signals
-5.13% $7.03
America/New_York / 8 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 578.58 mill |
| EPS: | -1.240 |
| P/E: | -5.67 |
| Earnings Date: | Aug 01, 2024 |
| SharesOutstanding: | 366.80 mill |
| Avg Daily Volume: | 3.06 mill |
| RATING 2024-05-08 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.67 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.21x |
| Company: PE -5.67 | industry: PE 27.41 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 6.55 - 7.51 ( +/- 6.88%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-29 | Paulson John | Buy | 5 890 | Common Shares, No Par Value |
| 2024-03-29 | Icahn Brett | Buy | 3 122 | Common Shares, No Par Value |
| 2024-03-29 | Robertson Russel C | Buy | 2 945 | Common Shares, No Par Value |
| 2024-03-29 | Wechsler Amy B | Buy | 647 | Common Shares, No Par Value |
| 2024-02-29 | Barresi John S | Buy | 39 126 | Common Shares, No Par Value |
| INSIDER POWER |
|---|
| 67.84 |
| Last 100 transactions |
| Buy: 2 132 507 | Sell: 336 154 |
Forecast:
16:00 - $7.02
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $7.02
Forecast 2: 16:00 - $7.02
Forecast 3: 16:00 - $7.02
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $7.03 (-5.13% ) |
| Volume | 6.37 mill |
| Avg. Vol. | 3.06 mill |
| % of Avg. Vol | 208.11 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BHC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BHC
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Latest Press Releases
2024-05-02 07:00:00 - Press Release
Bausch Health Announces First Quarter 2024 Results
First quarter revenues of $2.15 billion, up 11% on a reported and 8% on an organic1 basis year-over-year revenue growth in all segments on both a reported and organic1 basis gaap net loss attributable to bausch health companies inc. of $64 million adjusted ebitda attributable to bausch health companies inc. (non-gaap)1 of $665 million, up 13% xifaxan® appeal decision represents a significant milestone related to full separation of bausch + lomb reaffirmed full-year revenue and adjusted ebitda (non-gaap)1 guidance laval, qc / accesswire / may 2, 2024 / bausch health companies inc. (nyse:bhc)(tsx:bhc) ("bausch health" or the "company" or "we" or "our") today announced its first quarter 2024 financial results and other key updates from the quarter...
2024-04-11 16:22:00 - Press Release
Bausch Health To Announce First-quarter 2024 Results On May 2
Laval, qc / accesswire / april 11, 2024 / bausch health companies inc. (nyse:nhc)(tsx:bhc) will release first-quarter 2024 financial results on thursday, may 2, 2024. bausch health will host a conference call and live webcast at 8:00 a.m.
2024-04-11 13:03:00 - Press Release
Court Of Appeals For The Federal Circuit Issues Ruling In Norwich Case That Prevents Fda Approval Of Norwich's Abbreviated New Drug Application Until 2029
Laval, qc / accesswire / april 11, 2024 / bausch health companies inc. (nyse:bhc)(tsx:bhc), and its gastroenterology business salix pharmaceuticals, today announced that the u.s. court of appeals for the federal circuit in the matter of salix pharmaceuticals, ltd. et al v. norwich pharmaceuticals, inc., affirmed the may 17, 2023 decision of the u.s. district court for the district of delaware that had denied norwich pharmaceuticals, inc.'s motion for modification of the court's final order preventing the u.s. food and drug administration (fda) from approving its abbreviated new drug application (anda) for xifaxan (rifaximin) 550 mg before oct. 2, 2029.
2024-04-11 08:00:00 - Press Release
Acne Vulgaris Treatment Prarazlo(tm) (tazarotene Lotion, 0.045%) Now Available To Patients Through British Columbia Pharmacare Public Drug Plan
Laval, qc / accesswire / april 11, 2024 / bausch health, canada inc., part of bausch health companies inc. (nyse:bhc)(tsx:bhc), today announced that its topical prescription treatment for acne vulgaris, prarazlotm (tazarotene lotion, 0.045% w/w), is now available to patients through bc pharmacare, the public drug program of british columbia. arazlo is the only tazarotene lotion treatment approved by health canada for the topical treatment of acne vulgaris in patients 10 years of age and older.1 the listing by bc pharmacare means arazlo is now available to patients on all public drug plans across canada.
2024-04-05 18:15:00 - Press Release
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
Laval, qc / accesswire / april 5, 2024 / bausch health companies inc. (nyse:bhc)(tsx:bhc) along with its gastroenterology business, salix pharmaceuticals, inc., announced that it filed a lawsuit today in the united states district court for the district of new jersey against amneal pharmaceuticals of new york, llc, amneal eu, limited, amneal pharmaceuticals, llc, amneal pharmaceuticals private limited, and amneal pharmaceuticals, inc. this lawsuit follows receipt of a notice of paragraph iv certification stating that amneal submitted an abbreviated new drug application (anda) to the u.s. food and drug administration (fda) seeking approval to market a generic version of xifaxan® (rifaximin) 550 mg tablets...
Latest News
2024-05-03 10:36:14 - Zacks Investment Research
Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall
Bausch's (BHC) first-quarter earnings and sales miss their respective estimates. Its shares fall in response to the results.
2024-05-02 12:10:20 - Seeking Alpha
Bausch Health Companies (BHC) Q1 2024 Earnings Call Transcript
Bausch Health Companies [BHC] Q1 2024 Earnings Conference Call May 2, 2024 8:00 AM ET Company Participants Thomas Appio - CEO John Barresi - Interim CFO Garen Sarafian - IR Conference Call Participants Glen Santangelo - Jefferies Michael Nedelcovych - TD Cowen Douglas Miehm - RBC Capital Markets Umer Raffat - Evercore ISI Chi Fong - Bank of America David Amsellem - Piper Sandler Les Sulewski - Truist Securities Operator Greetings. Welcome to the Bausch Health first quarter 2024 earnings call.
2024-05-02 09:36:04 - Zacks Investment Research
Bausch Health (BHC) Q1 Earnings and Revenues Miss Estimates
Bausch Health (BHC) came out with quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.52 per share a year ago.
2024-04-29 13:06:12 - Zacks Investment Research
All You Need to Know About Bausch (BHC) Rating Upgrade to Buy
Bausch (BHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-04-11 16:22:00 - Accesswire
Bausch Health to Announce First-Quarter 2024 Results on May 2
LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m.
2024-04-11 13:15:22 - Zacks Investment Research
Will Bausch (BHC) Beat Estimates Again in Its Next Earnings Report?
Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
2024-04-11 13:03:23 - Reuters
Bausch wins US appeal to block Alvogen generic of diarrhea drug
A U.S. appeals court on Thursday affirmed a decision for Bausch Health that barred rival drugmaker Alvogen from marketing a proposed generic version of Bausch's diarrhea treatment Xifaxan until 2029.
2024-04-10 15:19:25 - Schaeffers Research
Pharma Stock Could Push Back Toward Highs
The shares of pharma stock Bausch Health Companies Inc (NYSE:BHC) have taken a tumble since their recent April 3 nearly two-year high of $11.46.
2024-04-08 14:31:08 - Zacks Investment Research
Bausch (BHC) Starts Litigation Against Amneal for Xifaxan
Bausch (BHC) initiates litigation against Amneal Pharmaceuticals and its subsidiaries over a generic version of its lead drug Xifaxan.
2024-04-03 10:56:12 - Zacks Investment Research
Here's Why Bausch Health (BHC) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.